Drugs / ALLO-ASC-DFU
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02394873 | Mar → Aug 2015 | — | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02394886 | Nov 2014 → May 2015 | ulcer of lower limbs | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03754465 | Jan 2019 → Oct 2023 | ulcer of lower limbs | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02619851 | Dec 2015 → Jul 2019 | — | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02619877 | Oct 2015 → Sep 2016 | ulcer of lower limbs | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04569409 | Jul 2020 → Dec 2024 | ulcer of lower limbs | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03370874 | Jun 2018 → Dec 2019 | ulcer of lower limbs | Anterogen Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-ASC-DFU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02619851 ↗ |
| Modality | Cell therapy | “ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells.” NCT02394873 ↗ |
| Route | Topical | “Application of ALLO-ASC-DFU sheet to diabetic foot ulcer” NCT02619877 ↗ |